3788 related articles for article (PubMed ID: 24139944)
21. Angiogenesis in rheumatoid arthritis.
Maruotti N; Cantatore FP; Crivellato E; Vacca A; Ribatti D
Histol Histopathol; 2006 May; 21(5):557-66. PubMed ID: 16493585
[TBL] [Abstract][Full Text] [Related]
22. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
24. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
26. The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells.
Kociok N; Heppekausen H; Schraermeyer U; Esser P; Thumann G; Grisanti S; Heimann K
Exp Eye Res; 1998 Aug; 67(2):237-50. PubMed ID: 9733590
[TBL] [Abstract][Full Text] [Related]
27. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
28. Investigating the role of angiogenesis in systemic lupus erythematosus.
Liu J; Wang X; Yang X; Yan Q; Wang S; Han W
Lupus; 2015 May; 24(6):621-7. PubMed ID: 25359881
[TBL] [Abstract][Full Text] [Related]
29. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
30. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
33. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy.
Tang J; Li Z; Lu L; Cho CH
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):533-42. PubMed ID: 24012659
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
Mittal K; Ebos J; Rini B
Semin Oncol; 2014 Apr; 41(2):235-51. PubMed ID: 24787295
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
36. Signaling pathways governing tumor angiogenesis.
Sakurai T; Kudo M
Oncology; 2011; 81 Suppl 1():24-9. PubMed ID: 22212932
[TBL] [Abstract][Full Text] [Related]
37. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6: an angiogenic target in solid tumours.
Middleton K; Jones J; Lwin Z; Coward JI
Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
[TBL] [Abstract][Full Text] [Related]
39. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders.
Laddha AP; Kulkarni YA
Respir Med; 2019 Sep; 156():33-46. PubMed ID: 31421589
[TBL] [Abstract][Full Text] [Related]
40. Lipoxins exert antiangiogenic and anti-inflammatory effects on Kaposi's sarcoma cells.
Marginean A; Sharma-Walia N
Transl Res; 2015 Aug; 166(2):111-33. PubMed ID: 25814167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
